TG Therapeutics Inc (NASDAQ:TGTX) – Equities researchers at Jefferies Group issued their FY2022 EPS estimates for TG Therapeutics in a report issued on Tuesday. Jefferies Group analyst M. Andrews expects that the biopharmaceutical company will post earnings of $1.12 per share for the year.
Several other equities research analysts also recently issued reports on TGTX. HC Wainwright reissued a “buy” rating and issued a $33.00 price objective (up from $18.00) on shares of TG Therapeutics in a research note on Tuesday, November 14th. B. Riley began coverage on TG Therapeutics in a report on Friday, December 1st. They set a “buy” rating and a $21.50 price target for the company. Raymond James Financial reissued a “buy” rating on shares of TG Therapeutics in a research note on Tuesday, December 12th. BidaskClub raised TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, January 11th. Finally, Zacks Investment Research lowered TG Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, January 13th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $25.50.
Hedge funds and other institutional investors have recently bought and sold shares of the company. BlackRock Inc. increased its position in shares of TG Therapeutics by 3.5% during the fourth quarter. BlackRock Inc. now owns 3,414,999 shares of the biopharmaceutical company’s stock valued at $28,003,000 after buying an additional 115,252 shares during the period. State Street Corp lifted its position in TG Therapeutics by 274.4% during the second quarter. State Street Corp now owns 2,638,683 shares of the biopharmaceutical company’s stock valued at $26,515,000 after purchasing an additional 1,933,896 shares during the period. Franklin Resources Inc. lifted its position in TG Therapeutics by 3.7% during the fourth quarter. Franklin Resources Inc. now owns 2,457,415 shares of the biopharmaceutical company’s stock valued at $20,151,000 after purchasing an additional 87,398 shares during the period. Vanguard Group Inc. lifted its position in TG Therapeutics by 14.3% during the second quarter. Vanguard Group Inc. now owns 2,046,427 shares of the biopharmaceutical company’s stock valued at $20,566,000 after purchasing an additional 255,844 shares during the period. Finally, Columbus Circle Investors lifted its position in TG Therapeutics by 9.8% during the third quarter. Columbus Circle Investors now owns 1,532,911 shares of the biopharmaceutical company’s stock valued at $18,165,000 after purchasing an additional 136,515 shares during the period. 47.44% of the stock is owned by institutional investors.
In related news, CFO Sean A. Power sold 32,006 shares of TG Therapeutics stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $8.50, for a total value of $272,051.00. Following the completion of the transaction, the chief financial officer now directly owns 517,464 shares in the company, valued at approximately $4,398,444. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 16.70% of the company’s stock.
About TG Therapeutics
TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.